Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4222-4234

  Umemiya, Hiroki ^a   Fukasawa, Hiroshi ^a   Ebisawa, Masayuki ^a   Eyrolles, Laurence ^a   Kawachi, Emiko ^a   Eisenmann, Ghislaine ^a   Gronemeyer, Hinrich ^a   Hashimoto, Yuichi ^b   Shudo, Koichi ^a   Kagechika, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DI TERT BUTYL 4' CHALCONECARBOXYLIC ACID; 4 (13H 10,11,12,13 TETRAHYDRO 10,10,13,13,15 PENTAMETHYLDINAPHTHO[2,3 B][1,2 E]DIAZEPIN 7 YL)BENZOIC ACID; 4 (7,8,9,10 TETRAHYDRO 5,7,7,10,10 PENTAMETHYL 5H BENZO[E]NAPHTHO[2,3 B][1,4]DIAZEPIN 13 YL)BENZOIC ACID; 4 [2,3 (2,5 DIMETHYL 2,5 HEXANO) 5 METHYL 5H DIBENZO[B,E][1,4]DIAZEPIN 11 YL]BENZOIC ACID; 4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; 4 [5H 2,3 (2,5 DIMETHYL 2,5 HEXANO) 5 METHYLDIBENZO[B,E][1,4]DIAZEPIN 11 YL]BENZOIC ACID; ALITRETINOIN; BENZOIC ACID DERIVATIVE; BEXAROTENE; DIAZEPINYLBENZOIC ACID DERIVATIVE; HX 630; HX 640; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; TAMIBAROTENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; TRANSLATION REGULATION;

AZEPINES; BENZOATES; BINDING, COMPETITIVE; CELL DIFFERENTIATION; DIBENZAZEPINES; DIMERIZATION; DRUG SYNERGISM; HL-60 CELLS; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS;

EID: 6844255855     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9704309     Document Type: Article

References (84)

1. Retinobenzoic Acids. VIII. The previous paper of this series: Eyrolles, L.; Kawachi, E.; Kagechika, H.; Hashimoto, Y.; Shudo, K. Synthesis and Biological Activity of Carboxyphenylquinolines and Related Compounds as New Potent Retinoids. Retinobenzoic Acids. VII. Chem. Pharm. Bull. 1994, 42, 2575-2581.
2. (a) Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds. The Retinoids, 2nd ed.; Raven Press: New York, 1994.
3. (b) Kastner, P.; Mark, M.; Chambon, P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 1995, 83, 859-869.
4. fa) Cunliffe, W. J., Miller, A. J., Eds. "Retinoid Therapy; MTP Press Limited: Lancaster, 1984.
5. (b) Bollag, W.; Holdener, E. E. Retinoids in cancer prevention and therapy. Ann. Oncol. 1992 3, 513-526.
6. (c) Hill, D. L.; Grubbs, C. J. Retinoids and cancer prevention. Annu. Rev. Nutr. 1992, 12, 161-181.
7. (a) Meng-er, H.; Yu-chen, Y.; Shu-rong, C.; Jin-ren, C.; Jia-xiang, L.; Lin, Z.; Long-jun, G.; Zhen-yi, W. Use of all-trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. Blood 1988, 72, 567-572.
8. (b) Castaigne, S.; Chomienne, C.; Daniel, M. T.; Ballerni, P.; Berger, R.; Fenaux, P.; Degos, L. All-trons Retinoic Acid as a Differentiation Therapy for Acute Promyelocytic Leukemia. I. Clinical Results. Blood 1990, 76, 1704-1709.
9. (c) de The, H. Altered retinoic acid receptor. FASEB J. 1996, 10, 955-960.
10. (d) Chomienne, C.; Fenaux, P.; Degos, L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 1996, 10, 1025-1030.
11. (a) Zitnik, R. J.; Kotloff, R. M.; Latifpour, J.; Zheng, T.; Whiting, N. L.; Schwalb, J.; Elias, J. A. Retinoic acid inhibition of IL-1-induced IL-6 production by human lung fibroblasts. J. Immunol. 1994, 152, 1419-1427.
12. (b) Chen, J.-Y.; Penco, S.; Ostrowski, J.; Balaguer, P.; Pons, M.; Starrett, J. E.; Reczek, P.; Chambon, P.; Gronemeyer, H. RAR-specific agonist/antagonists which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995, 14, 1187-1197.
13. (c) Kagechika, H.; Kawachi, E.; Fukasawa, H.; Saito, G.; Iwanami, N.; Umemiya, H.; Hashimoto, Y.; Shudo, K. Inhibition of IL-1-induced IL-6 Production by Synthetic Retinoids. Biochem. Biophys. Res. Commun. 1997, 231, 243-248.
14. (a) Ellis, C. N.; Voorhees, J. J. Etretinate therapy. J. Am. Acad. Dermatol. 1987, 16, 267-291.
15. (b) Ishibashi, Y. Rinsho Iyaku 1995, 77, 733-746.
16. (a) Mangelsdorf, D. J.; Evans, R. M. The RXR heterodimers and orphan receptors. Cell 1995, 83, 841-850.
17. (b) Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996, 10, 940-954.
18. (a) Forman, M.; Umesono, K.; Chen, J.; Evans, R. M. Unique Response Pathways Are Established by Allosteric Interactions among Nuclear Hormone Receptors. Cell 1995, 81, 541-550.
19. (b) Kurokawa R.; Söderström, M.; Hörlein, A.; Halachmi, S.; Brown, M.; Rosenfeld, M. G.; Glass, C. K. Polatiry-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995, 377, 451-454.
20. (c) Vivat, V.; Zechel, C.; Wurtz, J.-M.; Bourguet, W.; Kagechika, H.; Umemiya, H.; Shudo, K.; Moras, D.; Gronemeyer, H.; Chambon, P. A mutation mimicking the ligand-induced transconformation yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 1997, 16, 5697-5709.
21. (a) Bourguet, W.; Ruff, M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α, Nature 1995, 375, 377-382.
22. (b) Renaud, J.-P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378, 681-689.
23. Wurtz, J.-M.; Bourguet, W.; Renaud, J.-P.; Vivat, V.; Chambon, P.; Moras, D.; Gronemeyer, H. A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol. 1996, 3, 87-94.
24. (a) Hashimoto, Y.; Kagechika, H.; Shudo, K. Expression Of Retinoic Acid Receptor Genes And The Ligand-binding Selectivity Of Retinoic Acid Receptors (RAR's). Biochem. Biophys. Res. Commun. 1990, 166, 1300-1307.
25. (b) Matsushima, Y.; Kawachi, E.; Tanaka, H.; Kagechika, H.; Hashimoto, Y.; Shudo, K. Differentiation-Inducing Activity of Retinoic Acid Isomers and Their Oxidized Analogues on Human Promyelocytic Leukemia HL-60 Cells. Biochem. Biophys. Res. Commun. 1992, 189, 1136-1142.
26. (c) Hashimoto, Y.; Kagechika, H.; Kawachi, E.; Fukasawa, H.; Saito, G.; Shudo, K. Evaluation of Differentiation-Inducing Activity of Retinoids on Human Leukemia Cell Lines HL-60 and NB4. Biol. Pharm. Bull. 1996, 19, 1322-1328.
27. (a) Crettaz, M.; Baron, A.; Siegenthaler, G.; Hunziker, W. Ligand Specificities of Recombinant Retinoic Acid Receptors RARα and RARβ. Biochem. J. 1990, 272, 391-397.
28. (b) Graupner, G.; Malle, G.; Maignan, J.; Lang, G.; Pruniéras, M.; Pfahl, M. 6′-Substituted Naphthalene-2-carboxylic Acid Analogues, a New Class of Retinoic Acid Receptor Subtype-Specifie Ligands. Biochem. Biophys. Res. Commun. 1991, 179, 1554-1561.
29. (c) Delescluse, C.; Cavey, M. T.; Martin, B.; Bernard, B. A.; Reichert, U.; Maignan, J.; Darmon, M.; Shroot, B. Selective High Affinity Retinoic Acid Receptor α or β-γ Ligands. Mol. Pharmacol. 1991, 40, 556-562.
30. (d) Lehmann, J. M.; Dawson, M. I.; Hobbs, P. D.; Husmann, M.; Pfahl, M. Identification of retinoids with nuclear receptor subtype-selective activities. Cancer Res. 1991, 51, 4804-4809.
31. (e) Bernard, B. A.; Bernardon, J.-M.; Delescluse, C.; Martin, B.; Lenoir, M.-C.; Maignan, J.; Charpentier, B.; Pilgrim, W. R.; Reichert, U.; Shroot, B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem. Biophys. Res. Commun. 1992, 186, 977-983.
32. (f) Charpentier, B.; Bernardon, J.-M.; Eustache, J.; Millois, C.; Martin, B.; Michel, S.; Shroot, B. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes, J. Med. Chem. 1995, 38, 4993-5006.
33. (g) Teng, M.; Duong, T. T.; Klein, E. S.; Pino, M. E.; Chandraratna, R. A. S. Identification of a retinoic acid receptor a subtype specific agonist. J. Med. Chem. 1996, 39, 3035-3038.
34. (h) Yu, K-L.; Spinazze, P.; Ostrowski, J.; Currier, S. J.; Pack, E. J.; Hammer, L.; Roalsvig, T.; Honeyman, J. A.; Tortolani, D. R.; Reczek, P. R.; Mansuri, M. M.; Starrett, J. E., Jr. Retinoic Acid Receptor β, γ-Selective Ligands: Synthesis and Biological Activity of 6-Substituted 2-Naphthoic Acid Retinoids. J. Med. Chem. 1996, 39, 2411-2421.
35. (i) Johnson, A. T.; Klein, E. S.; Wang, L.; Pino, M. E.; Chandraratna, R. A. S. Identification of retinoic acid receptor β subtype specific agonists. J. Med. Chem. 1996, 39, 5027-5030.
36. (a) Lehmann, J. M.; Jong, L.; Fanjul, A.; Cameron, J. F.; Lu, X. P.; Haefher, P.; Dawson, M. I.; Phahl, M. Retinoids Selective for Retinoid X Receptor Response Pathways. Science 1992, 258, 1944-1946.
37. (b) Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and Structure - Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids J. Med. Chem. 1994, 37, 2930-2941.
38. (c) Beard, R. L.; Gil, D. W.; Marier, D. K.; Henry, E.; Colon, D. F.; Gillett, S. J.; Arefieg, T.; Breen, T. S.; Krauss, H.; Davies, P. J. A.; Chandraratna, R. A. S. Structural Basis for the Differential RXR & RAR Activity of Stilbene Retinoid Analogues. Bioorg. Med. Chem. Lett. 1994, 4, 1447-1452.
39. 3H]-9-czs-Retinoic Acid and Its Application for Identifying Retinoids with Unusual Binding Properties J. Med. Chem. 1994, 37, 408-414.
40. Shudo, K.; Kagechika, H. Structural Evolution of Retinoids Adv. Drug Res. 1993, 24, 81-119.
41. Nagy, L.; Thomázy, V. A.; Shipley, G. L.; Fésüs, L.; Lamph, W.; Heyman, R. A.; Chandraratna, R. A. S.; Davies, P. J. A. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. 1995, 15, 3540-3551.
42. (a) Kaneko, S.; Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinoid Antagonists. Med. Chem. Res. 1991, 1, 220-225.
43. (b) Eyrolles, L.; Kawachi, E.; Matsushima, Y.; Nakajima, O.; Kagechika, H.; Hashimoto, Y.; Shudo, K. Retinoid Antagonists: Molecular Design Based On The Ligand Superfamily Concept. Med. Chem. Res. 1991, 2, 361-367.
44. (c) Eyrolles, L.; Kagechika, H.; Kawachi, E.; Fukasawa, H.; Iijima, T.; Matsushima, Y.; Hashimoto, Y.; Shudo, K. Retinobenzoic acids. 6. Retinoid Antagonists with a Heterocyclic Ring. J. Med. Chem. 1994, 37, 1508-1517.
45. (a) Apfel, C.; Bauer, F.; Crettaz, M.; Forni, L.; Kamber, M.; Kaufmann, F.; LeMotte, P.; Pirson, W.; Klaus, M. A retinoic acid receptor a antagonist selectively countercts retinoic acid effects Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7129-7133.
46. (b) Keidel, S.; LeMotte, P.; Apfel, C. Different Agonist- and Antagonist-Induced Conformational Changes in Reetinoic Acid Receptors Analyzed by Protease Mapping. Mol. Cell. Biol. 1994, 14, 287-298.
47. (c) Lee, M.-O.; Hobbs, P. D.; Zhang, X.-K.; Dawson, M. I.; Pfahl, M. A synthetic retinoid antagonist inhibits the human immunodeficiency virus type 1 promoter. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 5632-5636.
48. (d) Johnson, A. T.; Klein, E. S.; Gillett, S. J.; Wang, L.; Song, T. K.; Pino, M. E.; Chandraratna, R. A. S. Synthesis and Characterization of a Highly Potent and Effective Antagonist of Retinoic Acid Receptors. J. Med. Chem. 1995, 38, 4764-4767.
49. (e) Yoshimura, H.; Nagai, M.; Hibi, S.; Kikuchi, K.; Abe, S.; Hida, T.; Higashi, S.; Hishinuma, I.; Yamanaka, T. A Novel Type of Retinoic Acid Receptor Antagonist: Synthesis and Structure-Activity Relationships of Heterocyclic Ring-Containing Benzoic Acid Derivatives. J. Med. Chem. 1995, 38, 3163-3173.
50. (f) Lee, M.-O.; Dawson, M. I.; Picard, N.; Hobbs, P. D.; Pfahl, M. A Novel Class of Retinoid Antagonists and Their Mechanism of Action. J. Biol. Chem. 1996, 277, 11897-11903.
51. (a) Koch, S. S. C.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the First Retinoid X Receptor Homodimer Antagonist. J. Med. Chem. 1996, 39, 3229-3234.
52. (b) Lala, D. S.; Mukherjee, R.; Schulman, I. G.; Canan-Koch, S. S.; Dardashti, L. J.; Nadzan, A. M.; Croston, G. E.; Evans, R. M.; Heyman, R. A. Activation of Specific RXR Heterodimers by an Antagonist of RXR Homodimers. Nature (London) 1996, 383, 450-453.
53. Liu, Y.; Lee, M. O.; Wang, H. G.; Li, Y.; Hashimoto, Y.; Klaus, M.; Reed, J. C.; Zhang, X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell Biol. 1996, 16, 1138-49.
54. Umemiya, H.; Kawachi, E.; Kagechika, H.; Fukasawa, H.; Hashimoto, Y.; Shudo, K. Chem. Pharm. Bull. 1995, 43, 1827-1829.
55. Umemiya, H.; Kagechika, H.; Fukasawa, H.; Kawachi, E.; Ebisawa, M.; Hashimoto, Y.; Eisenmann, G.; Erb, C.; Pornon, A.; Chambon, P.; Gronemeyer, H.; Shudo, K. Action Mechanism of Retinoid-Synergistic Dibenzodiazepines. Biochem. Biophys. Res. Commun. 1997, 233, 121-126.
56. (a) Olsson, I. L.; Breitman, T. R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′:5′-monophosphate-inducing agents. Cancer Res. 1982, 42, 3924-3927.
57. (b) Bollag, W.; Peck, R. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines Eur. J. Cancer 1991, 27, 53-57.
58. (c) Bollag, W. Retinoids and interferon: a new promising combination? Br. J. Haematol. 1991, 79 Suppl, 87-91.
59. 3-induced differentiation of leukemia HL-60 cells. Biochem. Biophys. Res. Commun. 1991, 178, 263-268.
60. (e) Safonova, I.; Reichert, U.; Shroot, B. Ailhaud, G.; Grimaldi, P. Fatty acids and retinoids act synergistically on adipose cell differentiation. Biochem. Biophys. Res. Commun. 1994, 204, 498-504.
61. (f) Sidell, N.; Wada, R.; Han, G.; Chang, B.; Shack, S.; Moore, T.; Samid, D. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer 1995, 60, 507-514.
62. (a) Roy, B.; Taneja, R.; Chambon, P. Synergistic Activation of Retinoic Acid (RA)-Responsive Genes and Induction of Embryonal Carcinoma Cell Differentiation by an RA Receptor α (RARα)-, RARβ- or RARγ-Selective Ligand in Combination with a Retinoid X Receptor-Specific Ligand. Mol. Cell. Biol. 1995, 75, 6481-6487.
63. (b) Lotan, R.; Dawson, M. I.; Zou, C.-C.; Jong, L.; Lotan, D.; Zou, C.-P. Enhanced Efficacy of Combinations of Retinoic Acid- and Retinoid X Receptor-selective Retinoids and α-Interferon in Inhibition of Cervical Carcinoma Cell Proliferation. Cancer Res. 1995, 55, 232-236.
64. (c) Apfel, C. M.; Kamber, M.; Klaus, M.; Mohr, P.; Keidel, S.; LeMotte, P. K. Enhancement of HL-60 Differentiation by a New Class of Retinoids with Selective Activity on Retinoid X Receptor. J. Biol. Chem. 1995, 270, 30765-30772.
65. (d) Chen, J. Y.; Clifford, J.; Zusi, C.; Starrett, J.; Tortolani, D.; Ostrowski, J.; Reczek, P. R.; Chambon, P.; Gronemeyer, H. Two distinct actions of retinoid-receptor ligands. Nature (London) 1996, 382, 819-822.
66. (e) Taneja, R.; Roy, B.; Plassat, J. L.; Zusi, C.; Ostrowski, J.; Reczek, P. R.; Chambon, P. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR β2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6197-6202.
67. (f) Minucci, S.; Leid, M.; Toyama, R.; Saint-Jeannet, J.-P.; Peterson, V. J.; Horn, V.; Ishmael, J. E.; Bhattacharyya, N.; Dey, A.; Dawid, I. B.; Ozato, K. Retinoid X Receptor (RXR) within the RXR-Retinoic Acid Receptor Heterodimer Binds Its Ligand and Enhances Retinoid-Dependent Gene Expression. Mol. Cell. Biol. 1997, 77, 644-655.
68. Collins, S. J.; Gallo, R. C.; Gallagher, R. E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature (London) 1977, 270, 347-349.
69. Koeffler, H. P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983, 62, 709-721.
70. Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo, R. C. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J. Exp. Med. 1979, 149, 969-974.
71. (a) Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. New-Type Inducers of Differentiation of Human HL-60 Promyelocytic Leukemia Cells. Terephtharic Anilides. Chem. Pharm. Bull. 1984, 32, 4209-4212.
72. (b) Kagechika, H.; Kawachi, E.; Hash-imoto, Y.; Himi, T.; Shudo, K. Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity. J. Med. Chem. 1988, 31, 2182-2192.
73. Retinoic acid has reproducibly a higher affinity to the recombinant RARγ protein used in our experiments than others. In the case of hydrophobic retinoids (i.e. retinoic acid), the binding constants significantly varied depending on the source of receptor (even RARa and -β) or experimental conditions.
74. Fukasawa, H.; Iijima, T.; Kagechika, H.; Hashimoto, Y.; Shudo, K. Expression of the Ligand-Binding Domain-Containing Region of Retinoic Acid Receptors α, βand γ in Escherichia coli and Evaluation of Ligand-Binding Selectivity. Biol. Pharm. Bull. 1993, 16, 343-348.
75. Roux, S.; Térouanne, B.; Balaguer, P.; Jausons-Loffreda, N.; Pons, M.; Chambon, P.; Gronemeyer, H.; Nicolas, J.-C. Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor. Mol. Endocrinol. 1996, 10, 1214-1226.
76. Schulman, I. G.; Li, C.; Schwabe, J. W. R.; Evans, R. M. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev. 1997, 77, 299-308.
77. (a) Leblane, B. P.; Stunnenberg, H. G. 9-Cis retinoic acid signaling: changing partners causes some excitement. Genes Dev. 1995, 9, 1811-1816.
78. (b) Kephart, D. D.; Walfish, P. G.; DeLuca, H.; Butt, T. R. Retinoid X Receptor Isotype Identity Directs Human Vitamin D Receptor Heterodimer Transactivation from the 24-Hydroxylase Vitamin D Response Elements in Yeast. Mol. Endocrinol. 1996, 10, 408-419.
79. (c) Lemon, B. D.; Freedman, L. P. Selective Effects of Ligands on Vitamin D3 Receptor- and Retinoid X Receptor-Mediated Gene Activation In Vivo. Mol. Cell. Biol. 1996, 16, 1006-1016.
80. (d) Mukherjee, R.; Jow, L.; Croston, G. E.; Paterniti, J. R., Jr. Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists J. Biol. Chem. 1997, 272, 8071-8076.
81. (e) Mukher-jee, R.; Davies, P. J. A.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nadzan, A. M.; Paterniti, J. R., Jr.; Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. J. Med. Chem. 1997, 386, 4407-410.
82. Our HL-60 cells are keeping the original character of the HL-60 cells. Takahashi, N.; Breitman, T. R. Induction of Differentiation and Covalent Binding to Proteins by the Synthetic Retinoidg Ch55 and Am80. Arch. Biochem. Biophys. 1994, 314, 82-89.
83. Takahashi, N. Cytotoxicity of Mercurial Preservatives in Cell Culture. Ophthalmic Res. 1982, 14, 63-69.
84. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.